ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2

NIH RePORTER · NIH · N01 · $2,035,373 · view on reporter.nih.gov ↗

Abstract

The company plans to obtain FDA approval for BP-C2, a lignin-derived polyphenolic complex with ammonium molybdate, as a topical and/or oral treatment against injuries associated with cutaneous radiation syndrome.

Key facts

NIH application ID: 10618127
Project number: 75N93020C00004-P00009-9999-1
Recipient: MEABCO INC
Principal Investigator: SERGEI PIGAREV
Activity code: N01
Funding institute: NIH
Fiscal year: 2022
Award amount: $2,035,373
Award type: —
Project period: 2020-05-01 → 2023-04-30